Health News Archive - February 25, 2009
New Health Trend MORAGA, Calif., Feb. 25 /PRNewswire/ -- Over 700,000 Americans visit emergency rooms each year due to adverse drug reactions from mainstream pharmaceutical drugs (JAMA). Adding insult to injury, many of these drugs are proving to be ineffective.
REINACH, Switzerland, February 25 /PRNewswire-FirstCall/ -- Arpida Ltd (SIX: ARPN) announced today its financial results for the year ending 31 December 2008. 2008 Key Events - Setback in regulatory process for intravenous iclaprim in US - Restructuring and focus on iclaprim - Top-line results of "intravenous-to-oral" Phase II trial with oral iclaprim - Leadership change - Share placing Cash and financial investments of CHF 38.7 million at 31 December 2008 Post-Year-End Event - January 2009: FDA issues Complete Response Letter 2009 Priorities - Finalise restructuring - Design a roadmap for approval of intravenous iclaprim - Consider and develop strategic options Dr Jurgen Raths, President and CEO, commented: "The negative FDA response of last January was a serious blow to our company and all of its stakeholders.
MOUNTAIN VIEW, California, February 25 /PRNewswire/ -- BN ImmunoTherapeutics, Inc. announced today that the first detailed data on PROSTVAC(TM) since the vaccine was licensed from the National Institutes of Health (NIH) is now available.
Grand Central Terminal Will Host Growers, Peanut Field, Product Sampling March 4 and 5 NEW YORK, Feb.
Comprehensive Reform Needed to Address Rising Health Costs and Lost Economic Opportunity WASHINGTON, Feb.
Ladies, a glass of wine a day may increase your chances of developing cancer.
IRVINE, Calif., Feb. 25 /PRNewswire/ -- Already a leader in the High Tech industry, New Momentum, provider of Enterprise Brand Intelligence software, is now offering its anti-counterfeiting software to pharmaceutical companies.
Laser Industry Executive to Head Company's Network of International Subsidiaries and Distributors WESTFORD, Mass., Feb. 25 /PRNewswire-FirstCall/ -- Cynosure, Inc.
SAN FRANCISCO, Feb. 25 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced the issuance of United States Patent No.
ABBOTT PARK, Ill., Feb. 25 /PRNewswire-FirstCall/ -- Abbott today announced the successful completion of the tender offer by its wholly owned subsidiary Rainforest Acquisition Inc. to purchase all of the outstanding shares of common stock of Advanced Medical Optics (AMO).